
Cigna (CI) Stock Forecast & Price Target
Cigna (CI) Analyst Ratings
Bulls say
Cigna Group is well-positioned in the healthcare industry, with a strong PBM and specialty pharmacy services segment that serves both insurance plans and employers. The recent merger with Express Scripts and new contracts with top-tier insurers, such as Centene, highlight the company's momentum and potential for growth. Additionally, its commitment to exiting the Exchange market and strategic review of its prior authorization unit show a focus on core growth opportunities. Despite potential economic impacts, Cigna's recent earnings beat and raised guidance indicate a positive outlook for the company's future performance.
Bears say
Cigna Group is facing headwinds in their PBM and health insurance services due to higher utilization and rate headwinds in the Medicare Advantage market. While the company is implementing measures to strengthen margins and has seen growth in its commercial membership, there are concerns around execution risk in managing medical cost trends and potential impact from regulatory changes on rebate economics. Additionally, the lack of a clear catalyst may limit market appetite for the stock, but the company's announcement of a September 2026 I-Day could reignite interest. The company's AI risk prediction model has shown early success in identifying complex patients and reducing unnecessary visits, but it remains to be seen if this can sustainably impact the company's bottom line. Overall, market conditions and potential risks make us maintain a negative outlook on Cigna Group's stock for the near future.
This aggregate rating is based on analysts' research of Cigna and is not a guaranteed prediction by Public.com or investment advice.
Cigna (CI) Analyst Forecast & Price Prediction
Start investing in Cigna (CI)
Order type
Buy in
Order amount
Est. shares
0 shares